World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT00404716
Date of registration: 28/11/2006
Primary sponsor: Shenyang Northern Hospital
Public title: Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation
Scientific title: Effects of Triple Versus Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Coronary Stent Implantation
Date of first enrolment: December 2004
Target sample size:
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00404716
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment  
Countries of recruitment
Contacts
Name:   Yaling Han, Dr.
Address: 
Telephone:
Email:
Affiliation:  Shenyang Northern Hospital
Key inclusion & exclusion criteria

Inclusion Criteria:

- Diagnosed with ACS Undergoing coronary stent implantation

- Between ages of above 18 Years and bellow 80 Years.

- Presence of one or several stenosis in native coronary arteries requiring PCI.

- Willing and able to sign informed consent.

Exclusion Criteria:

- A history of bleeding diathesis.

- New York Heart Association functional class IV.

- Prior PCI or coronary bypass grafting < 3 months.

- Contraindications to clopidogrel and aspirin (White blood cells counts < 4×109/L or
platelet counts <100 g.l-1 ;creatinine clearance <25 ml • min-1 ;active liver
disease).

- Use of glycoprotein IIb/IIIa inhibitors before PCI.

- Preparing to undergo CABG

- Taken clopidogrel or cilostazol recently



Age minimum: 18 Years
Age maximum: 80 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Acute Coronary Syndrome
Intervention(s)
Drug: Cilostazol
Primary Outcome(s)
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history